Dicot Pharma AB
SSTO:DICOT0.21
SEK
+0.00
(+1.03%)
Dicot Pharma AB
STO:DICOT
(Nasdaq Stockholm)
Recent
price
0.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- Dicot Pharma AB is a clinical-stage biopharmaceutical company that develops novel, long-acting therapeutic treatments for sexual dysfunctions and metabolic conditions. Founded in 2015 and headquartered in Uppsala, Sweden, the company operates within the biotechnology and pharmaceutical research industry, managing early-stage discovery, preclinical development, clinical trials, and intellectual property portfolios while pursuing licensing agreements and commercial partnerships with global pharmaceutical corporations for downstream commercialization and distribution. The company's core development pipeline and product candidates comprise LIB-01 for erectile dysfunction, a first-in-class small-molecule limonoid derivative engineered to modulate the melanocortin pathway and peripheral neurovascular mechanisms to provide sustained therapeutic efficacy lasting multiple weeks; LIB-01 for premature ejaculation, a dual-action oral pharmaceutical candidate targeting central and peripheral ejaculatory reflex pathways; and preclinical research programs evaluating limonoid-based active compounds for metabolic diseases and energy homeostasis disorders. Dicot Pharma AB conducts its research and corporate operations in Sweden, with multi-center clinical studies and regulatory engagements extending across Europe and the United States. In recent developments, the company changed its corporate name from Dicot AB to Dicot Pharma AB in May 2024 to underscore its clinical transition; successfully completed the clinical phase of its Phase 2a trial of LIB-01, confirming efficacy and a prolonged therapeutic duration of up to eight weeks; advanced preparations and clinical trial applications for international Phase 2b clinical trials across Europe and the United States; expanded its preclinical discovery scope into metabolic indications; strengthened its global patent portfolio across seven patent families with protections extending through 2042; and completed substantial capital raises, including an oversubscribed rights issue and directed share issue raising approximately SEK 231 million to fund its international clinical trial program and pipeline development.